ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

CONCLUSION: The combination of ZO met its primary endpoint of a superior ORR versus O, and demonstrated meaningful activity and a manageable safety profile in patients with R/R FL. ZO had a favorable benefit-risk profile compared with O, and represents a potential combination therapy for patients with R/R FL.PMID:37506346 | DOI:10.1200/JCO.23.00775
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research